AGC Biologics announces Alberto Santagostino as our new Chief Executive Officer and President.

Under new leadership, AGC Biologics will be “Your friendly CDMO expert.”?

Alberto brings two decades of biopharma industry service, and experience with how to grow a CDMO business at scale. AGC Biologics will re-emphasize the importance of delivering “friendly” and “expert” services to the biopharma industry. This direction builds on the company’s 30 years of global biopharma CDMO experience, including serving 250+ customers across 400+ different projects, launching 25 commercial products, and managing 90+ successful regulatory inspections. AGC Biologics aspires to become an easy choice. We will be a friendly CDMO to work with, a safe harbor for those customers seeking to minimize geopolitical risks, intellectual property concerns, steep price expectations or confrontational supplier relationships.?

Read more about Alberto’s expertise below. The full press release is available at https://www.agcbio.com/news/new-ceo-alberto-santagostino.

Alberto joins us from Lonza where he led the Cell and Gene Technology (CGT) Business Unit for six years. During his tenure, he led the industrialization of CGT therapeutics manufacturing: from a “science workshop” into “industrial scale compliant operations”, with several positive Pre-Approval Inspections (PAI) from the U.S. FDA and EMA. This led to three CGT biomanufacturing sites becoming licensed for commercial supply, four CGT therapies launched commercially, and several thousand patients being cured each year. Before Lonza, Alberto was a Partner of the Pharmaceutical & Medical Product practice at McKinsey & Co. He served more than 70 clients and developed an operations benchmark that analyzed the performance of more than 30 biomanufacturing sites, yielding unique insights into biopharma operations. Alberto has a degree in Industrial Biotechnology, an MBA, and is a board member of the Alliance for Regenerative Medicine .

“I am excited to announce Alberto is joining us to lead AGC Biologics and set the tone for the coming years. We share the common vision of service, delivery and quality that is at the core of AGC Group’s business philosophy. He will enhance AGC Biologics’ reputation as an increasingly preferable CDMO in the industry,” said Tadashi Murano, President of AGC Life Science Company.?

“I am grateful for the opportunity to serve AGC Biologics’ team members and customers,” said Alberto Santagostino, new Chief Executive Officer at AGC Biologics. “We will have customers at the heart of our action and our technical talent as the enabler of our CDMO aspiration of friendly & expert services to the biopharma industry. Ultimately, we will be ‘#YourfriendlyCDMOexpert.’”?

?#biotech #pharma #Biopharma #pharmaceuticals #LifeScience #Biotechnology #advancedtherapies #genetherapy #Biopharmaceuticals #YourfriendlyCDMOexpert